Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 9/20 | 0.89 |
| ▸ | PTGDR | Q13258 | 8/20 | 0.89 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.81 |
| ▸ | HPGD | P15428 | 1/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.81 |
| ▸ | PDE2A | O00408 | 9/20 | 0.73 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.64 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.64 |
| ▸ | PTGIR | P43119 | 3/20 | 0.64 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.64 |
| ▸ | PTGFR | P43088 | 2/20 | 0.64 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9518470 | 0.94 | TBXA2R (1.00) | TBXA2RPTGDRMEN1ALDH1A1CYP3A4 | |
| SCHEMBL6949873 | 0.91 | PDE2A (0.85) | TBXA2RPTGDRMEN1ALDH1A1CYP3A4 | |
| SCHEMBL6901522 | 0.91 | PTGDR (0.81) | TBXA2RPTGDRMEN1ALDH1A1CYP3A4 | |
| SCHEMBL6907420 | 0.91 | TBXA2R (0.80) | TBXA2RPTGDRMEN1ALDH1A1CYP3A4 | |
| SCHEMBL6903085 | 0.91 | TBXA2R (0.80) | TBXA2RPTGDRMEN1ALDH1A1CYP3A4 | |
| SCHEMBL10471370 | 0.90 | TBXA2R (0.78) | TBXA2RPTGDRMEN1ALDH1A1CYP3A4 | |
| SCHEMBL3044967 | 0.90 | MEN1 (1.00) | TBXA2RPTGDRMEN1ALDH1A1CYP3A4 | |
| SCHEMBL6948603 | 0.89 | TBXA2R (0.77) | TBXA2RPTGDRMEN1ALDH1A1CYP3A4 | |
| SCHEMBL6949862 | 0.89 | TBXA2R (0.77) | TBXA2RPTGDRMEN1ALDH1A1CYP3A4 | |
| SCHEMBL6903358 | 0.89 | PTGDR (0.77) | TBXA2RPTGDRMEN1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0310179-A2 | Tetrahydrocarbazole esters | MERCK FROSST CANADA INC. (CA) | 1989-04-05 | — | — | EP | claimed |
| EP-0307077-A1 | Tetrahydrocarbazoles for the improvement of cyclosporin therapy | MERCK FROSST CANADA INC. (CA) | 1989-03-15 | — | — | EP | claimed |
| EP-0300676-A2 | Tetrahydrocarbazole 1-alkanoic acids | MERCK FROSST CANADA INC. (CA) | 1989-01-25 | — | — | EP | claimed |
| US-20040092477-A1 | Compositions for the treatment and prevention of arterial thrombosis and use of an inhibitor of factor Xa alone and/or in combination with an anti-platelet aggregation agent | SANOFI-AVENTIS (FR) | 2004-05-13 | — | — | US | disclosed |
| US-6541488-B1 | Synergistic combination of a pentasaccharide sulfamate and ethyl N-(1-ethoxycarbonylmethylpiperidin-4-yl)-N-(4-(4-((N -ethoxycarbonylimino)(amino)methyl)phenyl)-thiazol-2-yl)-3-aminopropionate | SANOFI-SYNTHELABO (FR) | 2003-04-01 | — | — | US | disclosed |
| US-4940719-A | Tetrahydrocarbazole esters, pharmaceutical compositions and use | MERCK FROSST CANADA, INC. (CA) | 1990-07-10 | — | — | US | disclosed |
| EP-0310179-A2 | Tetrahydrocarbazole esters | MERCK FROSST CANADA INC. (CA) | 1989-04-05 | — | — | EP | disclosed |
| EP-0307077-A1 | Tetrahydrocarbazoles for the improvement of cyclosporin therapy | MERCK FROSST CANADA INC. (CA) | 1989-03-15 | — | — | EP | disclosed |
| US-4808608-A | ANTIALLERGENS, HYPOTENSIVE AGENT, ANTICOAGULANT | MERCK & CO., INC. (US) | 1989-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092477-A1 | Compositions for the treatment and prevention of arterial thrombosis and use of an inhibitor of factor Xa alone and/or in combination with an anti-platelet aggregation agent | SERPINC1, PLAT, F12 | TBXA2R 28/4885PTGDR 517/4885MEN1 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.